New Zealand approves MDMA for PTSD
Analysis based on 7 articles · First reported Sep 04, 2026 · Last updated Sep 05, 2026
The approval may boost the psychedelic therapy sector and related pharmaceutical companies, potentially increasing investment and research. It could also pressure other regulators to reconsider MDMA's therapeutic use, affecting the broader mental health treatment market.
New Zealand's pharmaceutical regulatory body New Zealand — Medsafe has approved two psychiatrists to prescribe pharmaceutical-grade MDMA for the treatment of severe post-traumatic stress disorder (PTSD). This makes New Zealand the second country in the world to approve MDMA for PTSD, following Australia's 2023 decision. Deputy Prime Minister David Seymour endorsed the move, citing the effectiveness of psychedelic-assisted therapy. The Ministry of Health in New Zealand clarified that treatment will be combined with psychotherapy and administered in controlled clinical settings, with patients aged 18 or older. The approval follows the U.S. United States — Food and Drug Administration's rejection of MDMA's medicinal use in 2024 due to insufficient evidence. Clinical trials continue in the United States, and a study in Israel suggested MDMA helped trauma victims of the Nova music festival attack.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard